FOXF1 Inhibits Pulmonary Fibrosis by Preventing CDH2-CDH11 Cadherin Switch in Myofibroblasts
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by aberrant accumulation of collagen-secreting myofibroblasts. Development of effective therapies is limited due to incomplete understanding of molecular mechanisms regulating myofibroblast expansion. FOXF1 transcription factor is expressed in resident lung fibroblasts, but its role in lung fibrosis remains unknown due to the lack of genetic mouse models. Through comprehensive analysis of human IPF genomics data, lung biopsies, and transgenic mice with fibroblast-specific inactivation of FOXF1, we show that FOXF1 inhibits pulmonary fibrosis. FOXF1 deletion increases myofibroblast invasion and collagen secretion and promotes a switch from N-cadherin (CDH2) to Cadherin-11 (CDH11), which is a critical step in the acquisition of the pro-fibrotic phenotype. FOXF1 directly binds to Cdh2 and Cdh11 promoters and differentially regulates transcription of these genes. Re-expression of CDH2 or inhibition of CDH11 in FOXF1-deficient cells reduces myofibroblast invasion in vitro. FOXF1 inhibits pulmonary fibrosis by regulating a switch from CDH2 to CDH11 in lung myofibroblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“An increase in bronchoalveolar (BAL) immune cells number has been identified as a predictive biomarker of progressive lung diseases, including IPF (Wynn and Ramalingam, 2012; Shen et al., 1988).”
ToppGene Suite for gene list enrichment analysis and candidate gene prioritization
Chen, J., Bardes, E. E., Aronow, B. J., & Jegga, A. G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp427 · Cited by 2,952
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Detecting differential usage of exons from RNA-seq data
Anders, S., Reyes, A., & Huber, W. (2012) · Genome Research · doi:10.1101/gr.133744.111 · Cited by 1,545
Fibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10875-10894.2005 · Cited by 627 · cited 1×
“FOXM1 is a well-known transcriptional activator of cell-cycle regulatory genes, such as Cdc25B, Cyclin B1, Plk1, Topo2, and Aurora B kinase (Wang et al., 2005).”
Pulmonary fibrosis: patterns and perpetrators
Noble, P. W., Barkauskas, C. E., & Jiang, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60323 · Cited by 595
Time course of bleomycin‐induced lung fibrosis
Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., & Breuer, R. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00220.x · Cited by 447
Dulauroy, S., Di Carlo, S. E., Langa, F., Eberl, G., & Peduto, L. (2012) · Nature Medicine · doi:10.1038/nm.2848 · Cited by 418 · cited 8×
“Various fibroblast markers include PDGFRα, TBX4, DESMIN, VIMENTIN, and -COL1a1 (Hung et al., 2013; Rock et al., 2011; Hinz et al., 2007; Xie et al., 2016; Dulauroy et al., 2012; Lovgren et al., 2011).”
InfluentialSevere lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44
Li, Y., Jiang, D., Liang, J., Meltzer, E. B., Gray, A., Miura, R., Wogensen, L., Yamaguchi, Y., & Noble, P. W. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102510 · Cited by 382
Myofibroblast development is characterized by specific cell-cell adherens junctions
Hinz, B., Pittet, P., Smith-Clerc, J., Chaponnier, C., & Meister, J.-J. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-05-0386 · Cited by 231 · cited 2×
“Myofibroblast differentiation was associated with increased CDH11 and decreased CDH2 levels, as well as changes in functional phenotypes of pathogenic myofibroblasts (Pittet et al., 2008; Hinz et al., 2004).”
Cited by
Myofibroblasts and Fibrosis: Mitochondrial and Metabolic Control of Cellular Differentiation
Gibb, A. A., Lazaropoulos, M. P., & Elrod, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.316958 · Cited by 434
Multi-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
Pakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis
Tai, Y., Woods, E. L., Dally, J., Kong, D., Steadman, R., Moseley, R., & Midgley, A. C. (2021) · Biomolecules · doi:10.3390/biom11081095 · Cited by 240
Lodyga, M., Cambridge, E., Karvonen, H. M., Pakshir, P., Wu, B., Boo, S., Kiebalo, M., Kaarteenaho, R., Glogauer, M., Kapoor, M., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aao3469 · Cited by 181
“CDH11 has since become a widely used marker for MFs in some normal tissues (25) and in various fibroproliferative conditions (26), including lung fibrosis (27, 28), skin fibrosis (29), kidney epithelial-to-mesenchymal transition (30), calcific aortic stenosis (31, 32), and Dupuytren disease (33).”
Background
Metadata
- Authors
- Black, M., Milewski, D., Le, T., Ren, X., Xu, Y., Kalinichenko, V. V., & Kalin, T. V.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 23
- Issue
- 2
- Pages
- 442-458
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2797650369
- Cited by
- 89
- References
- 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.